JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB81371

Anti-Sumo 2 + Sumo 3 antibody [8A2]

4

(7 Reviews)

|

(84 Publications)

Anti-Sumo 2 + Sumo 3 antibody [8A2] (ab81371) is a mouse monoclonal antibody detecting Sumo 2 + Sumo 3 in Western Blot, IHC-P, ICC/IF. Suitable for Human, Mouse, Rat.

- Over 60 publications
- Trusted since 2009

View Alternative Names

SMT3B, SMT3H2, SUMO2, Small ubiquitin-related modifier 2, SUMO-2, HSMT3, SMT3 homolog 2, SUMO-3, Sentrin-2, Ubiquitin-like protein SMT3B, Smt3B, SMT3A, SMT3H1, SUMO3, Small ubiquitin-related modifier 3, SUMO-3, SMT3 homolog 1, SUMO-2, Ubiquitin-like protein SMT3A, Smt3A

9 Images
Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Immunocytochemistry/immunofluorescence analysis of HeLa cells labelling Sumo 2 + Sumo 3 with ab81371 at 1/50 dilution. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Primary antibody, ab81371 at 1 : 50 was incubated overnight at 4° C, followed by AlexaFluor® 488-conjugated Goat anti- Mouse secondary antibody (ab150113) at 1/1000 dilution at RT for 45 min. ab179513 Anti-beta Tubulin, used as a counterstain at 1/200 dilution, was co-incubated with ab81371 overnight at 4° C, followed by Alexa Fluor® 594 Goat Anti-Rabbit. secondary (ab150080) at 1/1000 dilution at RT for 45 min. Nucleus were visualized using DAPI.

Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Immunocytochemistry/immunofluorescence analysis of SW480 cell line labelling Sumo 2 + Sumo 3 with ab81371 at 1/50 dilution. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Primary antibody, ab81371 at 1 : 50 was incubated overnight at 4° C, followed by AlexaFluor® 488-conjugated Goat anti- Mouse secondary antibody (ab150113) at 1/1000 dilution at RT for 45 min. ab179513 Anti-beta Tubulin, used as a counterstain at 1/200 dilution, was co-incubated with ab81371 overnight at 4° C, followed by Alexa Fluor® 594 Goat Anti-Rabbit. secondary (ab150080) at 1/1000 dilution at RT for 45 min. Nucleus were visualized using DAPI.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Immunohistochemical analysis of paraffin-embedded mouse kidney tissue labeling Sumo 2 + Sumo 3 with ab81371 at 1/1000 dilution followed by a ready to use Goat Anti-Mouse IgG H&L (HRP polymer) (ab214879). The section was incubated with ab81371 for overnight at 4℃.
Secondary antibody only control : Ready to use Goat Anti-Mouse IgG H&L (HRP polymer) (ab214879).
Heat mediated antigen retrieval with citrate buffer (pH 6.0, epitope retrieval solution1).

Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Immunocytochemistry/immunofluorescence analysis of NIH/3T3 cells labelling Sumo 2 + Sumo 3 with ab81371 at 1/50 dilution. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Primary antibody, ab81371 at 1 : 50 was incubated overnight at 4° C, followed by AlexaFluor® 488-conjugated Goat anti- Mouse secondary antibody (ab150113) at 1/1000 dilution at RT for 45 min. ab179513 Anti-beta Tubulin, used as a counterstain at 1/200 dilution, was co-incubated with ab81371 overnight at 4° C, followed by Alexa Fluor® 594 Goat Anti-Rabbit. secondary (ab150080) at 1/1000 dilution at RT for 45 min. Nucleus were visualized using DAPI.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Immunohistochemical analysis of paraffin-embedded rat kidney tissue labeling Sumo 2 + Sumo 3 with ab81371 at 1/1000 dilution followed by a ready to use Goat Anti-Mouse IgG H&L (HRP polymer) (ab214879). The section was incubated with ab81371 for overnight at 4℃.
Secondary antibody only control : Ready to use Goat Anti-Mouse IgG H&L (HRP polymer) (ab214879).
Heat mediated antigen retrieval with citrate buffer (pH 6.0, epitope retrieval solution1).

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • WB

Lab

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Buffer and concentration : 5% NFDM/TBST

All lanes:

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (ab81371) at 1/1000 dilution

Lane 1:

HeLa (human cervix adenocarcinoma epithelial cell), whole cell lysate B276 at 10 µg

Lane 2:

SH-SY5Y (human neuroblastoma epithelial cell), whole cell lysate at 10 µg

Lane 3:

K562 (human chronic myelogenous leukemia lymphoblast), whole cell lysate at 10 µg

Lane 4:

SW480 (human colorectal adenocarcinoma epithelial cell), whole cell lysate at 10 µg

Lane 5:

Jurkat (human T cell leukemia T lymphocyte), whole cell lysate at 10 µg

Lane 6:

293T (human embryonic kidney epithelial cell), whole cell lysate at 10 µg

Lane 7:

PC-12 (rat adrenal gland pheochromocytoma), whole cell lysate at 10 µg

Lane 8:

NIH/3T3 (mouse embryonic fibroblast), whole cell lysate at 10 µg

Secondary

All lanes:

Peroxidase-Conjugated Goat anti-Mouse IgG (H+L) at 1/10000 dilution

Predicted band size: 12 kDa

Observed band size: 15 kDa

false

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • WB

Unknown

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Dilution and concentration : 5% NFDM/TBST

All lanes:

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (ab81371) at 1/1000 dilution

Lane 1:

Human brain tissue lysate at 10 µg

Lane 2:

Human kidney tissue lysate at 10 µg

Lane 3:

Human spleen tissue lysate at 10 µg

Lane 4:

Mouse brain tissue lysate at 10 µg

Lane 5:

Rat spleen tissue lysate at 10 µg

Secondary

All lanes:

Peroxidase-Conjugated Goat anti-Mouse IgG (H+L) at 1/10000 dilution

Predicted band size: 12 kDa

Observed band size: 15 kDa

false

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • WB

CiteAb

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Western Blotting using Anti-Sumo 2 + Sumo 3 antibody [8A2], ab81371. Publication image from Eifler, K. et al., 2018, Nat Commun, 29549242. Legend direct from paper.

Knockdown of the SUMO conjugation pathway delays transition through mitosis and induces the formation of chromosome bridges. a Knockdown of the SUMO-activating enzyme (SAE) in HeLa cells was achieved by stably expressing inducible shRNAs generated against both SAE subunits SAE1 (ishSAE1) and SAE2 (ishSAE2.1 and ishSAE2.2). Scrambled shRNA was used as a control (ishControl). These cells were analyzed by live cell microscopy 48 h after induction of the SAE knockdown. Pictures were acquired every 5 min and a selection of pictures is depicted here. Scale bars correspond to 10 µM. b The amount of time needed for cells to pass from nuclear envelope breakdown (NEB) to metaphase (dark grey) and from metaphase to anaphase (light grey) was quantified by live cell imaging. Standard deviations were calculated for >200 cells resulting from three independent experiments. A two-sided Student’s t-test was performed. *p-values < 0.05. c To confirm a reduction of SUMO conjugates and SAE2 expression, lysates of HeLa cells expressing inducible SAE knockdown constructs were analyzed by immunoblotting with anti-SUMO2/3 and anti-SAE2 antibody 48 h after induction and compared to the control. Equal loading of the lysates was verified by staining with Ponceau S. d HeLa cells expressing inducible SAE knockdown constructs were fixed 72 h after induction and stained with Hoechst to monitor the formation of chromosome bridges (white arrows). Scale bars correspond to 10 µM. e The percentage of cells with DNA bridges 72 h after induction of SAE knockdown was quantified using the microscopy approach described above, analyzing 100 cells per condition. The standard error of the mean was calculated from three independent experiments. A two-sided Student’s t-test was performed. *p-values < 0.005

false

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)
  • WB

CiteAb

Western blot - Anti-Sumo 2 + Sumo 3 antibody [8A2] (AB81371)

Western Blotting using Anti-Sumo 2 + Sumo 3 antibody [8A2], ab81371. Publication image from Eifler, K. et al., 2018, Nat Commun, 29549242. Legend direct from paper.

Posttranslational modification of the APC/C by SUMOylation. a Alignment of the Cullin domains present in the human Cullin proteins and the Cullin-like domain of APC2 : The NEDDylated lysine residue within the Cullin proteins is highlighted in red and is absent in APC2. b HeLa cells were treated with DMSO as a negative control (−) or 1 µM MLN4924 (+), an inhibitor of the NEDD8-activating enzyme, for 16 h. Lysates were analyzed by immunoblotting with anti-APC2 and anti-CUL4A antibodies. Ponceau S staining was performed to monitor equal loading. c HeLa cells and HeLa cells expressing His-tagged SUMO2 (His-SUMO2) were subjected to a His-pulldown (His-PD). Input and pulldown samples were analyzed by immunoblotting making use of anti-APC4 and anti-SUMO2/3 antibodies. Blots were stained with Ponceau S to monitor equal loading. At least three independent experiments were performed and representative results are shown

false

  • Carrier free

    Anti-Sumo 2 + Sumo 3 antibody [8A2] - BSA and Azide free

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

8A2

Isotype

IgG2b

Carrier free

No

Reacts with

Mouse, Rat, Human

Applications

IHC-P, ICC/IF, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

This antibody recognizes Sumo 2 and 3 but does not recognize Sumo 1.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/2000", "ICCIF-species-notes": "<p></p>" }, "Mouse": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/2000", "ICCIF-species-notes": "<p></p>" }, "Rat": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Product details

What is this antibody validated in?
Anti-Sumo 2 + Sumo 3 antibody [8A2] (ab81371) is a mouse recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat samples.

What is the molecular weight of Sumo 2 + Sumo 3?
Anti-Sumo 2 + Sumo 3 [8A2] (ab81371) specifically detects a band for Sumo 2 + Sumo 3 (UniProt: P61956) at a molecular weight of 12kDa.

Trusted by the scientific community
Anti-Sumo 2 + Sumo 3 [8A2] (ab81371) was first used in a scientific publication in 2009 and has been cited over 60 times in peer-reviewed journals.

Reviewed by scientists
Anti-Sumo 2 + Sumo 3 [8A2] (ab81371) has over 5 independent reviews from customers.

Other related products
We have a range of other formats of antibody clone [8A2] also available for your convenience: ab81371, Carrier free - ab252805

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Sumo 2 and Sumo 3 are small ubiquitin-like modifier proteins involved in post-translational modification often referred to as SUMOylation. Alternately known as SUMO-2 and SUMO-3 these proteins weigh approximately 11 kDa each and are widely expressed across various tissues including the heart and brain. During stress conditions cells significantly increase the conjugation of these proteins to other cellular proteins thereby altering their functions subcellular localization or interactions.
Biological function summary

Sumo 2 and Sumo 3 play essential roles in numerous cellular processes by modifying several target proteins in the nucleus and cytoplasm. They are part of a complex regulatory system that modulates processes like nuclear transport chromosome segregation and DNA repair. Sumo 2/3 often work in tandem with other members of the SUMO family including SUMO-1 to ensure proper cellular homeostasis.

Pathways

Sumo 2 and Sumo 3 are intimately involved in fundamental cellular signaling pathways such as the p53 pathway and NF-κB pathway. These proteins modulate the activity of key proteins within these pathways including the tumor suppressor p53 and the transcription factor NF-κB which regulate cell survival proliferation and apoptosis. Sumo 2/3-related modifications can alter the stability and function of these proteins thereby influencing cellular response to stimuli.

Alterations in Sumo 2 and Sumo 3 functionality have been associated with neurodegenerative diseases and various cancers. In neurodegenerative disorders like Huntington's disease abnormal SUMOylation of specific proteins affects neuronal survival and function. Similarly in cancer dysregulation of SUMOylation pathways can affect the expression and activity of the oncogenic protein c-Myc contributing to tumor progression. These associations underline the significant role of Sumo 2/3 in pathophysiology.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2, CBX4 or ZNF451 (PubMed : 26524494). This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins (PubMed : 18408734, PubMed : 18538659, PubMed : 21965678, PubMed : 9556629). Plays a role in the regulation of sumoylation status of SETX (PubMed : 24105744).
See full target information SUMO2

Additional targets

SUMO3

Publications (84)

Recent publications for all applications. Explore the full list and refine your search

Nucleic acids research 53: PubMed40744492

2025

SUMO operates from a unique long tandem repeat to keep innate immunity in check.

Applications

Unspecified application

Species

Unspecified reactive species

Amandine Goffeney,Ivo A Hendriks,Victoria Morel,Yann Loe-Mie,François Charon,Michael L Nielsen,Jack-Christophe Cossec,Daan Noordermeer,Jacob-Sebastian Seeler,Anne Dejean

Nature communications 16:6261 PubMed40623999

2025

YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice.

Applications

Unspecified application

Species

Unspecified reactive species

Wenchao Li,SaiSai Chen,Jian Lu,Weipu Mao,Shiya Zheng,Minhao Zhang,Tiange Wu,Yurui Chen,Kai Lu,Chunyan Chu,Chuanjun Shu,Yue Hou,Xue Yang,Naipeng Shi,Zhijun Chen,Lihua Zhang,Lei Zhang,Rong Na,Ming Chen,Shenghong Ju,Dingxiao Zhang,Yi Ma,Bin Xu

Frontiers in immunology 16:1577781 PubMed40534859

2025

Integrated machine learning and single-cell analysis reveal the prognostic and therapeutic potential of SUMOylation-related genes in ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Zhengrong Deng,Yicong Xu,Peidong Zhang,Yixiang Peng,Jiaxing Tan,Zihang Chen,Yimei Ma

Theranostics 15:6369-6386 PubMed40521184

2025

SUMOylation of SARS-CoV-2 spike protein is a key target for broad-spectrum antiviral therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Xinyu Wang,Gaowei Hu,Yupeng Shao,Zhongwei Dong,Lina Liu,Yixuan Wang,Yaxi Xie,Nuoya Yu,Caixia Zhu,Fang Wei,Yuping Jia,Yuyan Wang,Qiliang Cai

Cell death discovery 11:230 PubMed40348773

2025

SUMO2/3 modification of transcription-associated proteins controls cell viability in response to oxygen and glucose deprivation-mediated stress.

Applications

Unspecified application

Species

Unspecified reactive species

Francisco Gallardo-Chamizo,Román González-Prieto,Vahid Jafari,Noelia Luna-Peláez,Alfred C O Vertegaal,Mario García-Domínguez

Cells 14: PubMed39937027

2025

Comprehensive SUMO Proteomic Analyses Identify HIV Latency-Associated Proteins in Microglia.

Applications

Unspecified application

Species

Unspecified reactive species

Fergan Imbert,Dianne Langford

Organogenesis 21:2460269 PubMed39905673

2025

The Role of SUMO1 Modification of SOX9 in Cartilage Development Stimulated by Zinc Ions in Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Na Xue,Jing Zhao,Jing Yin,Liang Liu,Zhong Yang,Shuchao Zhai,Xiyun Bian,Xiang Gao

The Journal of biological chemistry 300:107319 PubMed38677512

2024

Senp7 deficiency impairs lipid droplets maturation in white adipose tissues via Plin4 deSUMOylation.

Applications

Unspecified application

Species

Unspecified reactive species

Jingwen Pei,Dayuan Zou,Lu Li,Lulu Kang,Minli Sun,Xu Li,Qianyue Chen,Danning Chen,Bin Qu,Xiang Gao,Zhaoyu Lin

Nature structural & molecular biology 31:1355-1367 PubMed38649616

2024

Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferation.

Applications

Unspecified application

Species

Unspecified reactive species

Julio C Y Liu,Leena Ackermann,Saskia Hoffmann,Zita Gál,Ivo A Hendriks,Charu Jain,Louise Morlot,Michael H Tatham,Gian-Luca McLelland,Ronald T Hay,Michael Lund Nielsen,Thijn Brummelkamp,Peter Haahr,Niels Mailand

Nature microbiology 9:988-1006 PubMed38538832

2024

FEAR antiviral response pathway is independent of interferons and countered by poxvirus proteins.

Applications

Unspecified application

Species

Unspecified reactive species

Emily A Rex,Dahee Seo,Sruthi Chappidi,Chelsea Pinkham,Sabrynna Brito Oliveira,Aaron Embry,David Heisler,Yang Liu,Moiz Munir,Karolin Luger,Neal M Alto,Flávio Guimarães da Fonseca,Robert Orchard,Dustin C Hancks,Don B Gammon
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com